Crossmark

Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma

Crossref DOI link: https://doi.org/10.1186/s13148-018-0517-9

Published Online: 2018-06-18

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bensaid, Douae

Blondy, Thibaut

Deshayes, Sophie

Dehame, Virginie

Bertrand, Philippe

Grégoire, Marc

Errami, Mohammed

Blanquart, Christophe http://orcid.org/0000-0002-0917-3747
Funding

Funding for this research was provided by:

Region Pays de la Loire (DesEpiD)

Institut de Recherche en Santé Respiratoire des Pays de la Loire

Ligue Contre le Cancer

INSERM (France)/ CNRST (agreement 2015/2016)
License Information

Text and Data Mining valid from 2018-06-18
More Information

Article History

Received: 29 January 2018

Accepted: 11 June 2018

First Online: 18 June 2018

Ethics approval and consent to participate

: Mesothelioma cell line use in this work belongs to a bio-collection of mesothelioma samples from patients (DC-2011-1399) recognized by the French ministry of research. All recruited patients had received no prior anticancer therapy and gave signed, informed consent.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.